The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.

Babies treated with antibiotics in the first few weeks of their life are likely to show weaker immune responses to essential ...

Immunization programs save millions of lives every year by protecting against preventable diseases. The immune response to ...

Bacterial pneumonia is most commonly caused by a bacteria called Streptococcus pneumoniae which accounts for around 50% of cases. Other common causes include Haemophilus influenzae, Chlamydia ...

VAX-24 has the potential to cover more serotypes than any infant pneumococcal vaccine on-market today and provide protection ... The Company is developing broad-spectrum conjugate and novel protein ...

The 13-valent pneumococcal conjugate vaccine (PCV13) has obtained the corresponding drug production license and has submitted a registration application to the National Medical Products Administration ...

It develops broad-spectrum conjugate and novel protein vaccines to prevent ... Vaxcyte recently showed data suggesting that their pneumococcal vaccine is better than the current vaccines on the market ...

Capvaxive is a pneumococcal vaccine specifically designed to help protect adults ... for more cases of IPD in adults compared to PCV20 (pneumococcal 20-valent conjugate vaccine), as shown in these ...

Merck MRK announced that the European Commission (“EC”) has approved its 21-valent pneumococcal conjugate vaccine (“PCV”), Capvaxive, for the prevention of invasive pneumococcal disease ...